Clinical Trial: A Phase II Trial to Evaluate the Clinical Efficacy, Safety and Tolerability of MAS825 in Pediatric and Adult Participants With Still's Disease

U.S., Oct. 3 -- ClinicalTrials.gov registry received information related to the study (NCT07203001) titled 'A Phase II Trial to Evaluate the Clinical Efficacy, Safety and Tolerability of MAS825 in Pediatric and Adult Participants With Still's Disease' on Sept. 09.

Brief Summary: The study is a phase II trial designed to evaluate the clinical efficacy, safety, and tolerability of MAS825 in pediatric and adult participants with Still's disease

Study Start Date: Oct. 11

Study Type: INTERVENTIONAL

Condition: Still's Disease

Intervention: DRUG: MAS825

Experimental drug

Recruitment Status: NOT_YET_RECRUITING

Sponsor: Novartis Pharmaceuticals

Published by HT Digital Content Services with permission from Health Daily Digest....